January 2026 in “Addiction Biology” Finasteride may help reduce alcohol cravings and related brain activity.
Finasteride reduces DHT levels and affects gene expression in fish, similar to its effects in humans.
May 2025 in “Actas Dermo-Sifiliográficas” High-dose oral minoxidil can improve hair growth but may cause side effects.
1 citations
,
January 2021 in “European Journal of Inflammation” Methylated flavonoids may effectively reduce depression and inflammation caused by finasteride.
October 2023 in “Journal of pharmaceutical investigation” Finasteride dosages should be adjusted based on CYP3A5 genotype and liver function to avoid side effects.
2 citations
,
January 2022 in “Skin appendage disorders” Low-dose oral minoxidil effectively promotes hair growth but has associated risks.
1 citations
,
July 2020 in “Reviews in separation sciences”
May 2024 in “Journal of cosmetic dermatology” Topical finasteride/minoxidil is effective but not better than oral finasteride for hair loss.
June 2025 in “Frontiers in Neurology” Finasteride use is linked to a higher risk of memory problems.
1 citations
,
November 2021 in “Ultrasonography” Ultrasound boosts finasteride's hair growth effects in mice.
April 2026 in “Journal of Clinical Medicine” Stopping finasteride can lead to lasting sexual and psychological issues.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
33 citations
,
August 2016 in “Indian Journal of Dermatology, Venereology and Leprology” Dutasteride is more effective than finasteride at increasing hair count and reversing hair thinning in men with hair loss, but both have similar side effects.
2 citations
,
December 2021 in “Pharmaceutics” Finasteride-loaded proniosomes effectively promote hair growth in mice.
1 citations
,
December 2022 in “Pharmaceutics” Finasteride-loaded microemulsions can effectively enhance skin delivery for treating hair loss.
1 citations
,
July 2012 in “Der Urologe” Finasteride effectively reduces prostate size and symptoms in most BPH patients.
1 citations
,
March 2012 in “Acta Pharmaceutica Sinica B” New methods can detect finasteride's major urinary metabolite in urine for up to 49 hours.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
August 2025 in “Journal of Industrial and Engineering Chemistry” A new topical finasteride formulation effectively promotes hair growth with fewer side effects.
Combined oral minoxidil and finasteride significantly improve hair density in men with male pattern baldness.
January 2025 in “Heliyon” Tamsulosin and finasteride have similar effects on blood sugar control in men with type 2 diabetes.
January 2025 in “Annals of Dermatology” Low-dose dutasteride effectively and safely promotes hair growth in men.
January 2023 in “Skin appendage disorders” Low-dose oral minoxidil may help treat hair loss but is not FDA-approved and can cause side effects like unwanted hair growth and heart issues.
January 2025 in “Clinical Dermatology Review” Finasteride 5 mg and topical minoxidil 5% effectively increase hair density in women, with finasteride 5 mg having the highest satisfaction.
36 citations
,
June 2014 in “PLOS ONE” Finasteride, a hair loss drug, may cause long-term sexual side effects due to changes in hormone receptor levels.
14 citations
,
May 2016 in “Therapeutic advances in urology” Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
March 2025 in “Chinese Medical Journal” Topical finasteride effectively and safely increases hair growth in men with hair loss.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” Topical finasteride is an effective and safer treatment for male hair loss.
10 citations
,
June 2016 in “PLOS ONE” Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.
8 citations
,
October 2021 in “The international journal of risk and safety in medicine” The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.